Pfizer mulling over COVID-19 R&D pact with BioNTech: report


Big Pharma Pfizer is mulling over a pact with partner BioNTech to develop a vaccine for COVID-19.

This is according to an interview from the U.S. giant’s Chief Scientific Officer Mikael Dolsten, who told Reuters it could work with the mRNA biotech to develop a vaccine, potentially more quickly than other routes, to combat the disease that is spreading quickly around the globe.

Dolsten, who met with President Donald Trump this week with other Big Pharma heads to talk about industry response to the virus, told the news wire: “We will share some of our thoughts with BioNTech also on what they do on COVID-19 and evaluate whether there are things that could merit to do together.”

Virtual Roundtable

ASCO Explained: Expert predictions and takeaways from the world's biggest cancer meeting

Join FiercePharma for our ASCO pre- and post-show webinar series. We'll bring together a panel of experts to preview what to watch for at ASCO. Cancer experts will highlight closely watched data sets to be unveiled at the virtual meeting--and discuss how they could change prescribing patterns. Following the meeting, we’ll do a post-show wrap up to break down the biggest data that came out over the weekend, as well as the implications they could have for prescribers, patients and drugmakers.

BioNTech, which is looking to rival Moderna with its mRNA platform (Moderna is also speeding along the COVID-19 vaccine development route), has already said it’s looking to follow suit in creating an inoculation.  

Pfizer and the European biotech have a deal dating back to 2018 using mRNA tech for flu vaccines, but this could now be expanded for the novel coronavirus fight.

RELATED: Pfizer pays BioNTech $120M upfront to form mRNA flu vaccine pact

It would be joining a host of other pharmas, including Johnson & Johnson and Sanofi, that are teaming up to try to create a vaccine.

Suggested Articles

Insitro picked up $143 million to build out its technology, pursue new targets and advance treatments for genetically defined patient groups.

Generation Bio filed for a $215 million IPO to advance a pair of gene therapies for liver disease and push one of them into the clinic.

The IPO will push Avidity's lead muscle disorder program through IND-enabling studies and into the clinic in 2021.